<p>11 月 19 日（路透社）- Eyepoint Pharmaceuticals Inc (EYPT.O)：
* Eyepoint 宣布独立数据安全监测委员会对 Duravyu™ 在湿性年龄相关性黄斑变性中的关键第三阶段试验给予积极推荐。
* Eyepoint Pharmaceuticals Inc - Lugano 的顶线数据预计在 2026 年中期发布。</p>

EYPT

<p>11 月 19 日（路透社）- Eyepoint Pharmaceuticals Inc：* Eyepoint 宣布独立数据安全监测委员会对 Duravyu™在湿性年龄相关性黄斑变性中的关键第三阶段试验给予积极推荐 * Eyepoint Pharmaceuticals Inc - Lugano 的顶线数据预计在 2026 年中期发布 来源文本：进一步的公司报道：</p>

<p>Nov 19 (Reuters) - EyePoint Pharmaceuticals Inc (EYPT.O) :
* EYEPOINT ANNOUNCES POSITIVE RECOMMENDATION FROM INDEPENDENT DATA SAFETY MONITORING COMMITTEE FOR PIVOTAL PHASE 3 TRIALS FOR DURAVYU™ IN WET AGE-RELATED MACULAR DEGENERATION
* EYEPOINT PHARMACEUTICALS INC - TOPLINE DATA FOR LUGANO EXPECTED MID-2026 Source text: Further company coverage: (EYPT.O)</p>
<div class="lb-trans"><p>11 月 19 日（路透社）- Eyepoint Pharmaceuticals Inc (EYPT.O)：
* Eyepoint 宣布独立数据安全监测委员会对 Duravyu™ 在湿性年龄相关性黄斑变性中的关键第三阶段试验给予积极推荐。
* Eyepoint Pharmaceuticals Inc - Lugano 的顶线数据预计在 2026 年中期发布。</p>
</div>

Eyepoint 宣布数据安全监测委员会对 Duravyu 的三期试验给予了积极的推荐